Insider Cluster (4 insiders) ·Filed Jul 9, 2026

IONS

IONIS PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago
Insider cluster: 4 insiders, $1.4M total
Actionable Insight • Neutral

These insider sales are immaterial and likely driven by routine portfolio diversification or tax planning. No actionable signal; focus on upcoming pipeline catalysts for IONS.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
IONS ▼ -2.90% at T+20d
NEUTRAL call ✗ call lost -2.90% · α vs SPY -5.33% · entry $58.25 → $56.56
Next anchor: T+60d due 9h ago
Latest observation: T+58 -41.42% FF3 residual α
Entry anchored
Jul 9, 03:59 PM ET
via exchange tick
T+1d
-2.93%
call -2.93% · α -2.15%
$56.54
settled 3mo ago
T+5d
-6.18%
call -6.18% · α -5.62%
$54.65
settled 3mo ago
T+20d
-2.90%
call -2.90% · α -5.33%
$56.56
settled 8w ago
T+60d
—
call — · α —
—
due 9h ago

Price Chart

Loading chart...

Executive Summary

A cluster of insider sales at Ionis Pharmaceuticals (IONS) totaling $1.36M over a 7-day window, involving the Chief Scientific Officer, Chief Development Officer, and two directors. The total value represents only ~0.01% of the company's $14B market cap, making the sales immaterial and likely routine portfolio diversification or tax-related. No actionable signal for traders.

Key Financial Metrics

Direction
selling
Total Value
$1.4M
Insiders
4

Key Facts

  • Four insiders sold shares: EVP/CSO Bennett ($463K), Director Diaz ($864K), EVP/CDO Kordasiewicz ($31K), and Director Klein ($8K)
  • Total open-market proceeds: $1.36M
  • Sales represent ~0.01% of IONS' $14B market cap
  • No CEO or CFO participated in the sales
  • No other material corporate events (earnings, M&A, restructuring) accompanied this cluster

Financial Impact

Insider sales totaling $1.36M, representing 0.01% of $14B market cap — negligible relative to company size.

Risk Factors

  • No material risk identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (33 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-IONS-1783639622793
20 reports for IONS
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +32.25%Jul 9, 2026
Filters
Rows
Reports for IONS — sortable, filterable
TypeNow
Sep 4, 2026
28d ago
8-K
BEARISH ★ 7/10
$56.71 $47.25▲ +16.68%▲ +15.56%$43.54 (+23.22%)
Sep 4, 2026
28d ago
8-K
BULLISH ★ 7/10
$58.09 $51.44▼ −11.45%▼ −10.24%$43.54 (−25.05%)
Jul 31, 2026
9w ago
Insider Buy
NEUTRAL ★ 4/10
$51.77 $56.56▲ +9.25%▲ +5.74%$43.54 (−15.90%)
Jul 29, 2026
9w ago
8-K
MIXED ★ 6/10
$54.04 $54.19▲ +0.28%▼ −5.25%$43.54 (−19.43%)
Jul 10, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$58.25 $54.65▼ −6.18%▼ −5.62%$43.54 (−25.25%)
Jul 9, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$58.25 $54.65▼ −6.18%▼ −5.62%$43.54 (−25.25%)
Jul 9, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$58.25 $54.65▼ −6.18%▼ −5.62%$43.54 (−25.25%)
Jul 9, 2026
12w ago
8-K
BEARISH ★ 7/10
$64.27 $54.65▲ +14.97%▲ +14.84%$43.54 (+32.25%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$79.19 $86.33▲ +9.02%▲ +8.75%$43.54 (−45.02%)
Jun 30, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$79.19 $86.33▲ +9.02%▲ +8.75%$43.54 (−45.02%)
Showing 10 of 20

US Market Status

Market Closed — Opens Mon (64h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 10, 2026